Obesity: an epidemic of the 21st century by Islam, Najmul
eCommons@AKU
Section of Diabetes, Endocrinology and
Metabolism Department of Medicine
March 2005
Obesity: an epidemic of the 21st century
Najmul Islam
Aga Khan University, najmul.islam@aku.edu
Follow this and additional works at: https://ecommons.aku.edu/
pakistan_fhs_mc_med_diabet_endocrinol_metab
Recommended Citation
Islam, N. (2005). Obesity: an epidemic of the 21st century. Journal of Pakistan Medical Association, 55(3), 118-123.
Available at: https://ecommons.aku.edu/pakistan_fhs_mc_med_diabet_endocrinol_metab/51
Review Article
Obesity:  An Epidemic of the 21st Century
Najmul Islam
Department of Medicine, Aga Khan University, Karachi.
Obesity is an excessive accumulation of fat in the
body. It can be assessed by various ways including Body
Mass Index (BMI), waist circumference, life insurance
tables, CT / MRI and absorptiometry. Body Mass Index
(BMI) is the most widely accepted means of assessing obe-
sity (weight in kilograms divided by the square of height in
meters). The relationship of BMI to total body and viscer-
al fat, and consequent complications varies between ethnic
groups.1 Asian population particularly those from South
East Asia have more fat and co-morbidities for any given
BMI, resulting in different suggested BMI cut-off points.2
Adult BMI cut offs (Table 1) cannot be used in children and
adolescents to assess obesity as BMI varies throughout
childhood. In children the BMI is higher in 2nd year of life
and then drops at ages 4-7 years rising slowly to adult val-
ues. BMI for age charts3 can be used in clinical practice to
assess obesity in children. According to these charts a child
is overweight having a BMI between 85th - 95th per-
centiles and obese above 95th centiles. Central obesity par-
ticularly visceral fat is a risk factor for metabolic syn-
drome. Waist circumference cut-offs have been internation-
ally accepted for adults (Table 2) but there are no interna-
tionally accepted criteria for waist circumference in chil-
dren.
Epidemiology of Obesity
The prevalence of obesity is steadily increasing
across the world particularly in the developed countries. In
1980, 39% of men and 32% of women in UK were over-
weight or obese and 1991 this figure rose to 53% and 44%
respectively.4
W.H.O. estimates the prevalence of obesity to be
4.8% in the developing countries, 17.1% in countries in
economic transition and 20% in the developed world.
More than one billion adults worldwide are overweight
and at least 300 million of them are clinically obese.5
The increase in prevalence of overweight and obesi-
ty is not limited to adults but is also affecting the children
even more. In Australian children over the decade 1985 -
1995 the combined prevalence of the two conditions almost
doubled while that of obesity on its own more than tripled.6
Etiology of Obesity 
The etiology of obesity is complex and multifactor-
ial. Both environmental and genetic influences play a role.
The recent increase in obesity is clearly due to
environmental factors i.e. easy availability of high-energy
food together with major reduction in physical activity that
has characterized human existence until recently. Examples
of changes in energy intake over the past 50 years are
shown in Table 3.
Not everybody who is exposed to obesogenic envi-
ronment due to affluence become obese, thus indicating
that a genetic predisposition is required. In adoption stud-
ies it has been shown that adoptees resemble their biologi-
cal parents in body size more than adoptive parents.7 Some
genes which predispose to obesity have been identified i.e.,
leptin, leptin receptor, POMC and Melanocortin-4 receptor.
Most instances of human obesity are thought to be poly-
genic.
Medical Consequences of Obesity
Obesity is associated with increased morbidity and
mortality. This has been known for more than 2000 years
and Hippocrates said, "Sudden death is more common in
those who are naturally fat than in the lean."
In obesity the excess energy is stored in fat cells that
enlarge and / or increase in number. Enlarged fat cells pro-
duce clinical problems associated with obesity either
because of mass of extra fat or because of increased secre-
tion of free fatty acids and numerous peptides from
enlarged cells.
Spectrum of medical condition results from obesity
some of which are as follows:
Diabetes Mellitus and Metabolic Syndrome  
Type 2 Diabetes is strongly associated with exces-
sive weight in both sexes in all-ethnic population.8,9 The
risk of diabetes increases with duration and degree of obe-
sity and with a more central distribution of body fat. In the
Nurses Health Study the risk of diabetes was lowest with
BMI less than 22 kg/m2. As BMI increased the relative risk
increased such that with a BMI of 35, the relative risk
increased 40 fold. A similar relationship was observed in
men in the Health Professional Follow up study. In the
same study it was shown that weight loss or moderating
weight gain over years reduces the risk of developing dia-
betes. Insulin resistance, a hallmark of Metabolic syndrome
is very high in overweight and obese. Subsequently all the
features of metabolic syndrome are more common in obese
subjects.
Hypertension  
Blood Pressure is often increased in obese and over-
weight subjects.10 Hypertension in obese subjects appears
to be related to altered sympathetic activities. The combi-
nation of overweight and hypertension leads to thickening
of ventricular wall and larger heart volume with a greater
likelihood of cardiac failure. 
Table 1. Classification of obesity.
Classification Caucasian Asian
Normal range 18.5 - 24.9 18.5 - 22.9
Overweight 25.0 - 29.9 23.0 - 25.9
Obese >30.0 >26
Class I 30.0 - 34.9 26.0 - 29.9
Class II 35.0 - 39.9 30.0 - 35.0
Class III >40.0 >35
Table 2. Waist circumfercine cutoff for central obesity.
Caucasian Asian
Men >102 > 90
Women > 88 > 80
Table 3. Examples of changes in energy intake and energy expendi-
ture over the past 50 years.
Energy Intake Energy expenditure
Cheaper food: Increased ownership of cars:
Greater availability of food: Change in work practices:
Supermarkets Construction machines 
Freezers Production lines 
Fast food outlets Computers
Change in diet composition: Labour-saving devices:
Increased fat Washing machines
Increased refined sugars Dishwashers
Less complex carbohydrates Remote controls
More alcohol Cordless phones
Change in eating patterns: Sedentary relaxation:
More snacks Television
Fewer 'family' meals Computer games
Increased portion size Lifts
Escalators
Children: Children:
Targeted by food industry Push chairs
Greater autonomy Fewer walk to school
Greater spending power Decreased sport at school
Dyslipidaemia  
A positive correlation between BMI and triglyc-
erides has been repeatedly demonstrated. An inverse rela-
tionship of BMI with HDL, the good cholesterol, is more
important as a risk factor for coronary artery disease.11
Heart disease
Data from the "Nurses Health Study"12 indicate that
the risk of women developing coronary artery disease is
increased greater than 3 folds with a BMI greater than 29.
Dyslipidaemia, Hypertension and Diabetes all contribute to
this increased risk. Aerobic Center Longitudinal Study13
involving 25714 men who were followed for 1-10 years has
shown that the cardiovascular mortality was higher in men
with BMI greater than 30 kg/m2.
Cancer
Certain cancers are significantly increased in over-
weight and obese individuals. These include malignant
neoplasm of colon, rectum and prostrate in men and can-
cers of breast, uterus and gallbladder in women.
Non-alcoholic fatty liver disease (NAFLD)
It is a disease having liver abnormalities associated
with obesity comprising of hepatomegaly, elevated liver
enzymes and abnormal liver histology.14 In a cross section-
al study involving liver biopsies in obese subjects have
shown steatosis in 75%, steatohepatitis in 20% and cirrho-
sis in 2%.15
Gallbladder disease
The clinical saying "fat, female, fertile and forty"
describes the epidemiology of gallbladder disease associat-
ed with cholelithiasis. Nurses Health Study has demon-
strated this very clearly. It has been shown that the inci-
dence of gallstones gradually increase with increased BMI
upto 30 and very steeply with higher BMI. One of the expla-
nations for increased risk of gallstones is the increased cho-
lesterol turnover related to increased body fat.
Diseases of the bones and joints
Osteoarthritis is significantly increased in obese
patients. The joints affected are usually the knees and
ankles and is directly related to trauma associated with the
degree of excess body weight.16 Increased osteoarthritis of
other non-weight hearing joint is also seen in obese
patients.
Sleep apnoea
Pulmonary functions are altered in obese patients
showing a decrease in residual long volume associated with
increased abdominal pressure on the diaphragm.17 In addi-
tion to this benign effect on pulmonary function obstructive
sleep apnoea is also seen more in obese tall-men.
Reproductive/Endocrine abnormalities
Variety of endocrine changes are seen in obese
patients but the changes in reproductive system in women
are most profound. Irregular, infrequent and an-ovulatory
menstrual cycles are common in obese women and the rate
of fertility is also reduced.18,19 Hirsuitism is also more
commonly seen in obese women who may be suffering
from P.C.O.S.
Increased mortality/shortened life expectancy
Framingham Study20 has shown loss of 3.3 years in
overweight women and 3.1 years in overweight men com-
pared with normal weight men and women. In obese
women and men these shortened life years are more pro-
nounced reaching 7.1 years and 5.8 years respectively.
Despite the fact that obesity is more common in African-
Americans than Caucasian-Americans, it is more lethal for
whites than blacks.21 Nurses Health Study12, American
Cancer Society Cancer Prevention Study II and I22,23 have
all shown increased mortality in both men and women with
BMI in the obese range.
Treatment of Obesity
Lifestyle modification
Lifestyle modification remains a cornerstone of
obesity treatment. It comprises of dietary modification,
increased activity and exercise and behavioral/cognitive
therapy. Aim of treatment is to produce clinically valuable
weight loss of 5 - 10% that is maintainable long term. Even
this modest weight loss is associated with significant bene-
fits as shown in Table 4 on the basis of data from Scottish
Intercollegiate Guidelines Network.24
Current dietary advise to obese patients is healthy
eating principles of reducing fat intake and to limit carbo-
hydrates especially those having a high glycaemic index,as
high insulin levels can encourage weight gain.25,26 A fixed
caloric deficit of 600 calories from the stable prior intake is
generally advised. This energy deficit can lead to a weight
loss of 0.5-0.6/wk.24 Very low energy diet (VLED) of 800
kcal can be tried in the initial weight loss plan but cannot
be maintained long term. The advise of a trained dietitian
can be of great help in this regard.
Increased physical activity is an important compo-
nent of lifestyle modification. A modest initial target of 30
minutes of brisk walking five days per week, which can be
increased gradually to 80 minutes of moderate intensity
activity per day.
Drug Therapy
Pharmacotherapy should be considered in over-
Drug Therapy
Pharmacotherapy should be considered in over-
weight / obese subjects with BMI greater than 27kg/m2 in
the presence of co-morbidities such as Type 2 Diabetes and
Hypertension when life style modification has not resulted
in desired weight loss. In the absence of co-morbidities a
BMI of 30and above is the cutoff to consider drug thera-
py.27 Only two drugs Sibutramine (Meridia, Reductil,
Abbott laboratories) and Orlistat (Xenical, Hoffman-
Laroche) are licensed for use in obesity by the Food and
Drug Administration for long-term use.
Sibutramine is a centrally acting drug that inhibits
nor epinephrine and serotonin re-uptake enhancing satiety
and suppressing hunger. It also attenuates the fall in meta-
bolic rate, which comes with weight loss. More than 10
prospective randomized controlled trials have supported its
efficacy.28,29 STORM trial30 of 2 years duration showed
that 69% of those receiving sibutramine achieved 5%
weight loss and 46% achieved 10% weight loss. On an
average systolic blood pressure increases by 4 mmHg and
diastolic by 2-4 mm Hg and heart rate increases by 4
beats/min on patients taking sibutramine. It is therefore
recommended that the blood pressure and the pulse rate be
monitored regularly (2 weekly in the first 3 months, month-
ly between 4-6 months and quarterly thereafter).
Orlistat, an inhibitor of pancreatic and gastrointesti-
nal lipases prevents absorption of approximately 30% of
dietary fat. More than 11 prospective randomized trials
have demonstrated its efficacy.28 Orlistat reduces LDL,
decreases the progression to diabetes and leads to better
glycemic control in diabetics.29 It has no systemic side
effects due to its lack of absorption. Gastrointestinal side
effects due to its mode of action include loose shoots,
increased defecation, faecal urgency and oily anal dis-
charge. Fat-soluble Vitamins Supplementation is recom-
mended 2 hours before or after taking Orlistat.
Some antidepressant including SSRI'S and SSNRI
affect body weight.31 Fluoxetine is the most studied drug
from this group and shows moderate weight reduction.
These drugs are not approved for treating obesity but
should be considered when treating depression in obese
and overweight patients.
Many compounds are currently undergoing clinical
trials as an anti-obesity agent including:
♣ Leptin or leptin receptor analogues that activate leptin
signaling cascade distal to leptin receptor
♣ Rimonabant, an inhibitor of the cannabinoid - 1- 
receptor 
♣ Amylin, a protein secreted by pancreatic beta cells
♣ Anti Ghrelin
♣ α MSH and MC4 receptor agonist 
♣ GLP - 1 agonist
♣ CCK agonist
Surgery
Life style modification has limited success resulting
in no more than 10% of total body weight. Bariatric surgery
is the only effective modality for long-term weight loss for
severely obese patients.32 They produce weight loss and
maintenance of 30 - 40%.
The indications for bariatric surgery are morbidly
obese patients with BMI >40 or obese patients with BMI >
35 with associated co-morbids.33 Bariatric surgeries are of
different types:
♣ Restrictive and Malabosptive
Gastric bypass (open or laproscopic)
Biliopancreatic diversion with duodenal switch
♣ Restrictive
Vertical banded gastroplasty (stomach stapling)
Laparoscopic adjustable gastric band
A comparison of different bariatic surgeries is
shown in Table 5.34 These surgeries are associated with sig-
nificant morbidity and mortality in inexperienced hands
and in centers not geared for it. Peri-operative mortality of
1% and a complication rate of 10% are reported from expe-
rienced centers across the world. Adjustable laproscopic
gastric banding is becoming the favoured approach because
Table 4. Benefits of a 10kg weight loss (based on data from Scottish
Intercollegiate Guidelines Network).
Mortality Lipids 
Reduction Reduction:
>20% total mortality 10% total cholesterol
>30% diabetes-related deaths 15% LDL
>40% obesity-related cancer deaths 30% triglycerides
Increases:
8% HDL
Blood pressure 
Reduction:
10mmHg systolic Respiratory
20mmHg diastolic Reduced sleep apnoea
Decreased breathlessness 
Diabetes
Reduction Gynaecological
50% fasting glucose Improved ovarian function and
fertility in PCOS
laproscopic gastric banding is becoming the
favoured approach because of its reversibility and low mor-
bidity. Excellent results have been reported for Europe and
Australia. For unclear reason s the results of this surgery in
USA is not very good.35 
Conclusion
Obesity is a chronic condition that predisposes
patients to multiple serious health disorders and premature
deaths. Body Mass Index is the most widely accepted
measure of obesity in adults. BMI though established
measure of obesity; waist circumference is gaining impor-
tance as it measures central obesity, which is an important
risk factor for metabolic syndrome.
The prevalence of obesity is steadily increasing
across the world particularly in developed countries. This
epidemic will continue to plaque our society for many
years with all its medical consequences. Although influ-
enced by genetics, the current obesity epidemic appears to
be driven principally by environmental factors. Lifestyle
factors of high-energy food intake and lack of physical
activity are the greatest contributors to the energy imbal-
ance that causes obesity. Treatment of obesity involves
dedicated and sustained lifestyle modification assisted by
anti-obesity drugs, which has modest effect in loosing
weight of 5-10%. Our growing understanding of the com-
plex mechanism of energy balance in our body will allow
the development of newer and safe drugs in this field.
Bariatric surgery is the only effective modality for long-
term weight loss for morbidly obese patients.
Major efforts are needed to curb the escalating inci-
dence of obesity globally. Prevention strategies should be
targeted which involves lifestyle interventions. Individual
and collective efforts at community and population levels
are needed if we are to stem this epidemic. Despite preven-
tion strategies, various treatment methods, eradication of
obesity does not appear to be on the scene in the foresee-
able future.
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